Abstracts Archive - Page 877 of 2425 - ACR Meeting Abstracts

Abstract Number: 1779 • 2019 ACR/ARP Annual Meeting
CLEC5A/MDL-1 Is Critical for Inflammatory Arthritis and Skin Inflammation
Cuong Nguyen¹, Dai Hui ¹, Ran Gu ¹, Trevor Chan ², Alina Marleev ³, Emanual Maverakis ³, Vijay Kuchroo ⁴, Shie-Liang Hsieh ⁵, Ilias Tagkopoulos ², Christopher Ritchlin ⁶ and Iannis Adamopoulos ¹, ¹Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Sacramento, CA, ²University of California, Davis, Department of Computer Science, California, USA, Davis, CA, ³Department of Dermatology, School of Medicine, UCD, Sacramento, California, USA., Sacramento, CA, ⁴Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, MA, USA, Boston, MA, ⁵Genomics Research Center, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ⁶Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Interleukin-23 (IL-23) and its cognate receptor interleukin-23R (IL-23R):IL-12Rβ1 plays a critical role in the pathogenesis of autoimmune diseases including psoriasis and psoriatic arthritis. Although…
Abstract Number: 1780 • 2019 ACR/ARP Annual Meeting
Microbiome in Offspring of Ankylosing Spondylitis Patients
Matthew Stoll¹, Kimberly DeQuattro ², Zhixiu Li ³, Henna Sawhney ⁴, Maria Castillo ⁴, Pamela F. Weiss ⁵, Peter Nigrovic ⁶, Lynn Punaro ⁷, Kenneth Schikler ⁸, Barbara Edelheit ⁹, John Reveille ¹⁰, Matthew Brown ³ and Lianne Gensler ¹¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of California, San Francisco, San Francisco, CA, ³Queensland University of Technology, Queensland, Australia, ⁴University of California in San Francisco, San Francisco, CA, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Boston Children's Hospital, Boston, MA, ⁷Texas Scottish Rite Hospital, Dallas, TX, ⁸University of Kentucky, Louisville, KY, ⁹Connecticut Children's Medical Center, Hartford, CT, ¹⁰University of Texas McGovern Medical School, Houston, ¹¹University San Francisco California, San Francisco, CA
Background/Purpose: Spondyloarthritis (SpA) results from the interplay between genetic and environmental factors. An emerging factor is the human intestinal microbiota, which multiple studies in children…
Abstract Number: 1781 • 2019 ACR/ARP Annual Meeting
Cytokine Dependence of Enthesis-resident Lymphocytes in Murine Spondyloarthritis
Mederbek Matmusaev ¹, Emma Haley¹, Imtiyaz Hossain ¹ and Joerg Ermann ¹, ¹Brigham and Women's Hospital, Boston
Background/Purpose: Enthesis-resident CD4-CD8- double-negative (DN) T cells have been implicated in the pathogenesis of spondyloarthritis. Overexpression of IL-23 in adult mice activates these cells to…
Abstract Number: 1782 • 2019 ACR/ARP Annual Meeting
A Human SLE Variant NCF1-R90H Drives Lupus-like Kidney Disease in a Pristane-induced Murine Lupus Model
Lin-Yu Geng¹, Ivan Molano ², Ling-Xiao Xu ³, Qing Sun ¹, Phillip Ruiz ⁴, Quan-Zhen Li ⁵, Gary Gilkeson ⁶ and Betty Tsao ⁷, ¹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ²Division of Rheumatology & Immunology/Medical University of South Carolina, Charelston, ³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charelston, SC, ⁴Department of Surgery/University of Miami School of Medicine, Charleston, ⁵Department of Immunology & Internal Medicine/University of Texas Southwestern Medical Center, Charleston, ⁶Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC, ⁷Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston
Background/Purpose: We previously identify a p.Arg90His (p.R90H) substitution encoded in phagocyte neutrophil cytosolic factor (NCF1) as a novel risk variant for SLE, with decreased and…
Abstract Number: 1783 • 2019 ACR/ARP Annual Meeting
Reversible Dysregulation of Renal Circadian Rhythm in Lupus Nephritis
Rakesh Mishra ¹, Ramalingam Bethunaickan ¹, Celine Berthier ², Zhengzi Yi ³, Joshua Strohl ¹, Patricio Huerta ¹, Weijia Zhang ⁴ and Anne Davidson⁵, ¹Feinstein Institute for Medical Research, manhasset, NY, ²University of Michigan, Ann Arbor, MI, ³Mount Sinai School of Medicine, New York, ⁴Mount Sinai School of Medicine, New York, NY, ⁵Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Circadian rhythm is a universal phenomenon that governs homeostasis of overall organism functioning as well as of individual organs. Circadian regulation of homeostatic functions…
Abstract Number: 1784 • 2019 ACR/ARP Annual Meeting
Single Cell Analysis of Renal Myeloid Cells from NZB/WF1 Mice with Lupus Nephritis Reveals Multiple Subsets with Altered Functions
Rakesh Mishra ¹, Celine Berthier ², Heather Geiger ³, Weijia Zhang ⁴ and Anne Davidson⁵, ¹Feinstein Institute for Medical Research, manhasset, NY, ²University of Michigan, Ann Arbor, MI, ³New York Genome Center, New York, NY, ⁴Mount Sinai School of Medicine, New York, NY, ⁵Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Renal infiltration with macrophages and dendritic cells is associated with poor prognosis in humans with lupus nephritis (LN). However, the precise pathogenic and/or protective…
Abstract Number: 1785 • 2019 ACR/ARP Annual Meeting
The Pathogenic Potential of Choroid Plexus T Cells in Neuropsychiatric Lupus
Erica Moore¹, Michelle Huang ¹, Cara Reynolds ¹ and Chaim Putterman ², ¹Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, New York, NY
Background/Purpose: The pathogenesis of neuropsychiatric Systemic Lupus Erythematosus (NPSLE) is incompletely understood, but is considered to be complex and multifactorial. Additionally, there is a wide…
Abstract Number: 1786 • 2019 ACR/ARP Annual Meeting
Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury
Sladjana Skopelja-Gardner¹, Xizhang Sun ², Yufeng Peng ², Lucrezia Colonna ², Payton Hermanson ², Lena Tanaka ², Joyce Tai ², David Salant ³ and Keith Elkon ², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle, ³Boston University, Boston
Background/Purpose: Lupus nephritis (LN) is a major contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Defective clearance of apoptotic cells (AC), autoantibodies, and…
Abstract Number: 1787 • 2019 ACR/ARP Annual Meeting
The Glucocorticoid-Induced Protein GILZ Represent a Checkpoint in the IFN Program in SLE
Eric Morand¹, Champa Nataraja ¹, Melissa Northcott ¹, Wendy Dankers ¹, Jacqueline Flynn ¹, Wendy Zhu ¹, Taylah Bennett ¹, Mehnaz Pervin ¹, Brendan Russ ¹, James Harris ¹ and Sarah Jones ¹, ¹Monash University, Melbourne, Victoria, Australia
Background/Purpose: Given the primacy of Type I interferon (IFN) pathways in SLE pathogenesis, and the near-ubiquity of glucocorticoid (GC) use in SLE treatment, clarifying the…
Abstract Number: 1788 • 2019 ACR/ARP Annual Meeting
Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome
Yu Zuo¹, Srilakshmi Yalavarthi ², Kelsey Gockman ², David Karp ³, Quan-Zhen Li ⁴ and Jason Knight ⁵, ¹University of Texas Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³UTSouthwestern Medical Center, Dallas, TX, ⁴Department of Immunology & Internal Medicine/University of Texas Southwestern Medical Center, Charleston, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Neutrophil extracellular traps (NETs) are prothrombotic tangles of chromatin and microbicidal proteins ejected from neutrophils in response to a variety of stimuli. In antiphospholipid…
Abstract Number: 1789 • 2019 ACR/ARP Annual Meeting
Defibrotide Inhibits Antiphospholipid Antibody-Mediated NET Release and Endothelial Cell Activation
Ramadan Ali¹, Hui Shi ¹, Srilakshmi Yalavarthi ¹ and Jason Knight ², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Defibrotide is a mixture of phosphodiester oligonucleotides derived from porcine intestinal mucosa, currently approved for treatment of hepatic sinusoidal obstruction syndrome. Defibrotide has been…
Abstract Number: 1790 • 2019 ACR/ARP Annual Meeting
The Epidemiology of the Antiphospholipid Syndrome in the UK, 1990 – 2016
Mia Rodziewicz¹, David D'Cruz ², Martin Gulliford ³ and Nisha Hazra ³, ¹The Louise Coote Lupus Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, ²The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom, ³School of Population Health and Environmental Sciences, King’s College London, London, United Kingdom
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterised by recurrent vascular thrombosis and/or pregnancy morbidity in the presence of persistently positive antiphospholipid autoantibodies.…
Abstract Number: 1791 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Antibody Profile Stability over Time: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Elena Gkrouzman¹, Ecem Sevim ², Jackie Finik ³, Danieli Andrade ⁴, Vittorio Pengo ⁵, Savino Sciascia ⁶, Maria Tektonidou ⁷, Amaia Ugarte ⁸, Cecilia Chighizola ⁹, H Michael Belmont ¹⁰, Laura Pérez Sánchez ¹¹, Lanlan Ji ¹², Paul Fortin ¹³, Maria Efthymiou ¹⁴, Guilherme De Jesus ¹⁵, David Branch ¹⁶, Cecilia Nalli ¹⁷, Michelle Petri ¹⁸, Ricard Cervera ¹⁹, Esther Rodriguez ²⁰, Jason Knight ²¹, Tatsuya Atsumi ²², Rohan Willis ²³, Maria Laura Bertolaccini ²⁴, Hannah Cohen ¹⁴, Jacob Rand ²⁵, Doruk Erkan ¹ and On Behalf Of APS ACTION ²⁶, ¹Hospital for Special Surgery, New York City, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, New York, NY, ⁴Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁵Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ⁷First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸Hospital Universitario Cruces, University of the Basque Country Autoimmune Diseases Research Unit, Department of Internal M edicine, BioCruces Health, Biscay, Spain, ⁹Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ¹⁰NYU Langone Health, New York, NY, ¹¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ¹²Peking University First Hospital, Beijing, China (People's Republic), ¹³Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁷Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹Hospital Clinic of Barcelona, Barcelona, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²²Hokkaido University, Sapporo, Japan, ²³Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, ²⁴King's College London, London, United Kingdom, ²⁵Weill Cornell Medicine, New York, ²⁶APS ACTION, New York, NY
Background/Purpose: APS ACTION "Registry" was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic autoimmune diseases. Our primary…
Abstract Number: 1792 • 2019 ACR/ARP Annual Meeting
Cognitive Dysfunction (CD) and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Primary Antiphospholipid Syndrome (PAPS)
Renata Rosa¹, Michelle Remião Ugolini-Lopes ², Ana Paula Gandara ², Kenia Campanholo ², Livia Dutra ³ and Danieli Andrade ⁴, ¹Faculdade de Medicina da Universidade de São Paulo (USP), Brazil., São Paulo, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo (USP), Brazil., São Paulo, Brazil, ³Escola Paulista de Medicina (EPM), Brazil, São Paulo, Brazil, ⁴Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Cognition dysfunction (CD) is a poorly understood non-stroke central neurologic manifestation of antiphospholipid syndrome, whose diagnosis involves a specific neuropsychological (NP) evaluation. Brain-derived neurotrophic…
Abstract Number: 1793 • 2019 ACR/ARP Annual Meeting
Descriptive Analysis of Biopsy-proven Antiphospholipid Antibody-associated Nephropathy Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Maxime Taghavi¹, Medha Barbhaiya ², Maria Tektonidou ³, Paul Fortin ⁴, Danieli Andrade ⁵, Jason Knight ⁶, Bahar Artim-Esen ⁷, Tatsuya Atsumi ⁸, Hannah Cohen ⁹, Lanlan Ji ¹⁰, Savino Sciascia ¹¹, Surya Seshan ¹², Doruk Erkan ¹³ and on Behalf of APS ACTION ¹⁴, ¹Brugmann Hospital, Brugmann, Belgium, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁴Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ⁵Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁶Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁷Istanbul University School of Medicine, Istanbul, Turkey, ⁸Hokkaido University, Sapporo, Japan, ⁹University College London, London, United Kingdom, ¹⁰Peking University First Hospital, Beijing, China (People's Republic), ¹¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ¹²Weill Cornell Medicine, New York, ¹³Hospital for Special Surgery, New York City, ¹⁴Hospital for Special Surgery, New York
Background/Purpose: Antiphospholipid antibody (aPL) nephropathy is a distinct entity that can be challenging to recognize and treat; it remains unknown if uniform pathologic criteria are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].